PBLA (PBLA) Stock Price & Analysis
PBLA (PBLA) rose 0.00% to USD 0.01 as of June 10, 2026 at 03:13 UTC, according to Nexqual real-time market data.
PBLA last closed at USD 0.01; the session ranged USD 0.02–0.02 on volume of 1,012 shares. Market capitalization is $53,888, with a 52-week range of USD 0–2.5 (PNK). Source: Nexqual, June 10, 2026 at 03:13 UTC.
Key Statistics (as of June 10, 2026 at 03:13 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.01 |
| Open | USD 0.02 |
| Day Range | USD 0.02 – 0.02 |
| 52-Week Range | USD 0 – 2.5 |
| Volume | 1,012 shares |
| Market Cap | $53,888 |
| Exchange | PNK |
Technical Analysis (PBLA)
Nexqual's technical model rates PBLA "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 03:13 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.94 (overbought) |
| vs SMA50 | Above (USD 0) |
| MACD | 0 (positive) |
Analyst Ratings (PBLA)
Wall Street analysts rate PBLA "None", per Nexqual as of June 10, 2026 at 03:13 UTC.
| Consensus Rating | None |
|---|
Earnings (PBLA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-06-30 | USD -1.47 vs est -1.7 ▲ beat |
| 2024-03-31 | USD -2.28 vs est -1.62 ▼ miss |
| 2023-12-31 | USD -65.9 vs est -217 ▲ beat |
| 2023-09-30 | USD -53.8 vs est -41.2 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Financials & Fundamentals (PBLA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.26 |
| Total Cash | $4.73M |
| Total Debt | $6.39M |
| Free Cash Flow | $-7.98M |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Financial Health Score (PBLA)
Nexqual rates PBLA's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:13 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $5M cash vs $6M debt |
| Cash Flow | Weak — Operating cash flow -$16M |
| Efficiency | Mixed — No data |
Ownership (PBLA)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 4.85M |
| Float | 4.85M |
| Short % of Float | +3.07% |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Leadership (PBLA)
PBLA is led by Jennifer K. Simpson CRNP, M.S.N. (age 57), CEO, President & Director, per Nexqual as of June 10, 2026 at 03:13 UTC.
| CEO, President & Director | Jennifer K. Simpson CRNP, M.S.N. (age 57) |
|---|---|
| VP of Finance, CFO, Secretary & Treasurer | Susan Horvath (age 66) |
| Vice President of Operations | Tammy Groene |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PXMD | PaxMedica, Inc. | USD 0 | ▲ 0% |
| NEXI | NexImmune, Inc. | USD 0 | ▲ 0% |
| ZVSA | ZyVersa Therapeutics, Inc. | USD 0.17 | ▼ 12.55% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.2 | ▲ 1.69% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:13 UTC. This page is informational and not investment advice.